OTLK
Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. (OTLK) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 56.9, with 3/3 trend checks passing.
OTLK with MA50 and MA200
Key levels & signals
Outlook Therapeutics, Inc. (OTLK) is still trading in a constructive trend overall. The latest available price is $1.56, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 61.8% and above the 200-day moving average by 68.0%.
OTLK currently has an RSI reading of 56.9, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.
For traders reviewing OTLK next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about OTLK
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.